Mark Brook

Biostatistician in The Division of Genetics and Epidemiology at @ICR_London

ORCID:

[Mark Brook @MarkNBrook]

A Personalised Clinical Dynamic Prediction Model to Characterise Prognosis for Patients with Localised Prostate Cancer: analysis of the CHHiP Phase III Trial https://t.co/SP6joI5uNw

[European Urology @EUplatinum]

Family History of Prostate Cancer and Survival Outcomes in the UK Genetic Prostate Cancer Study

https://t.co/eiOeijvrRa

@HolsUroLols @zx8754 @kotezsofi

[Burcu Darst @BurcuDarst]

Excited to see this work published! In a large sample of >22K African ancestry men, we show that a rare #HOXB13 variant found only in men of West African ancestry is associated with 2.4-fold higher risk of overall #prostatecancer and 5.1-fold higher risk of metastatic disease.

[Mark Brook @MarkNBrook]

"Risk of breast cancer in men in relation to weight change: a national case-control study in England and Wales"
Anthony Swerdlow, @CydneyLBruce, Rosie Cooke, Penny Coulson, @Minouk_Schoe, Michael Jones @AlchemiJones in IJC @intjcanc
https://t.co/GErlygKueT

[Hetan Shah @HetanShah]

Very sad that Hon Fellow of @BritishAcademy_ Sir David Cox has died. He was a towering figure in the field of statistics. I remember getting him to do one of the @RoyalStatSoc 180th anniversary lectures in 2014 when he was 90 and still on fine form https://t.co/QzCxWlz5ZQ

[Antonis Antoniou @antonis02]

Our manuscript on the evaluation of associations of BRCA1 and BRCA2 mutations with 22 different cancers (other than breast/ovarian cancers in women) out @JCO_ASCO. Analysed Data from >5000 families with mutations from CIMBA
@oncoalert #gcchat @CRUK_CI
https://t.co/pilm1YxIk2

[EAU Edu Platform UROONCO @EAU_Uroonco]

Results of the first screening round of the IMPACT study for men with mismatch repair genes pathogenic variants.

Read more 👇
https://t.co/ar06gOInDm

#prostatecancer #Movember

@marcobrooko @judeoffman @SapnaSyngal @roodvdb

[Mark Brook @MarkNBrook]

"A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study"
Elizabeth Bancroft @LizBancroft2, Elizabeth Page, Ros Eeles in @TheLancetOncol
https://t.co/Vpt8H9Ng6G

[The ICR @ICR_London]

"Our new findings show that PSA testing in men with #LynchSyndrome is much more likely to pick up life-threatening #ProstateCancer than in the general population." - Professor Rosalind Eeles, of the ICR and @royalmarsdenNHS.

Read more in @BBCNews.
https://t.co/Vaf9DoWFTu

[The ICR @ICR_London]

The PROFILE study aims to understand why some men, including black men, are at greater risk of #ProstateCancer.

Winston, Richard, Frederick, and Olivier explain why more men should sign up 👇🏿👇🏼👇🏾

#BlackInCancerWeek21 @cancerBRC @royalmarsdenNHS @ProstateUK @realpaulparker2

[Mark Brook @MarkNBrook]

@mitchiela @paulpharoah @siddhartha_kar Yes! I use this all the time when compliling large author lists. Really useful.

[The ICR @ICR_London]

📢 The ICR's and @royalmarsdenNHS' PACE-B trial showed that using advanced radiotherapy called SBRT to deliver precise treatment over a short time frame in #ProstateCancer, didn't lead to worse side effects compared to standard #Radiotherapy 👇
https://t.co/h87xX9zHxR

[Dr Adam Rutherford @AdamRutherford]

An interesting tale of science communication, journalism and the culture wars has just dropped - ​🧵
​@JenniferRaff @ewanbirney @aylwyn_scally @minouye271 + I recently published a paper about the lexicon of genetics, and how it needs to be addressed
https://t.co/BvgCYW5IWQ

[Prostate Cancer UK @ProstateUK]

"Thanks to you, this study will help us understand more about the genetics of prostate cancer."

@realpaulparker2 is taking part in our groundbreaking PROFILE study to help us understand why black men are twice as likely to get prostate cancer.

Join him: https://t.co/81eUPBZDo0

[Ewan Birney @ewanbirney]

A group of us (@minouye271, @JenniferRaff, @aylwyn_scally @AdamRutherford and myself) have written a piece on the language we use in genetics; untangling from previous sometimes racist language and being more precise and less harmful. We welcome feedback. https://t.co/hpLNqseHbw

[David Conti @dvconti]

Constructing and evaluating risk models in non-European ancestry populations is essential to broaden the impact of genomic medicine. Excited to be a part of this group @ChrisHaiman @johnwitte @GENES_PK and others supported by the consortium. @KECKSchool_USC @uscphs @USCBiostat

[george davey smith @mendel_random]

Looking forward to Stephen Chanock talking on “Radiation, genomic alterations in papillary thyroid carcinoma and transgenerational studies following the Chernobyl accident” @mrc_ieu online seminar 21st June 3pm UK time, all welcome https://t.co/icJjhP5V9f

[Bogdan Pasaniuc @bpasaniuc]

so excited to see this out. TWAS fails to implicate many risk regions as it focuses on steady-state expression levels. Enter CWAS, that uses chromatin variation to reveal context-dependent gene regulation as drivers of prostate cancer risk

https://t.co/PEykVRD3iM

[Burcu Darst @BurcuDarst]

Really nice editorial on our recent @EUplatinum publication describing the combined effect of rare and common variants in #ProstateCancer. Discusses the use of RPMs/PRS/fam hx for screening and next steps needed to evaluate the clinical utility of #PRS

https://t.co/lN7BmYrMCH